Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
Data From the Companies' Novel Heat Shock Protein 90 InhibitorReveal Further Evidence of Safety, Tolerability, and BiologicalActivity CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced updated interimresults from a Phase I clinical trial of the companies' heat shockpr...Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinicaldata on IPI-504 in a Phase I trial in patients withgastrointestinal stromal tumors (GIST) and other soft tissuesarcomas (STS), will be presented at the 2007 Annual Meeting of theAmerican Society of Clini...MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
Data Include Results from Phase 1 Studies with Monoclonal AntibodyTargeting Interleukin-9 (IL-9); Preclinical Data Provide FurtherRationale for IL-9 Inhibition in Developing Potential AsthmaTherapies GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the presentation of datahighlighting recent progress within the company's inflammatorydisease pipelin...